LIFT-TB

Completed

LIFT-TB

  • Intervention Area
  • 15 hospitals across 4 provinces (DKI Jakarta, West Java, Central Java, East Java)
  • Duration
  • July 2022 – September 2024
  • Funder
  • Korea International Cooperation Agency (KOICA) and TB Alliance through KNCV TB Foundation

Indonesia bears one of the world’s highest burdens of drug-resistant tuberculosis (DR-TB), with low treatment initiation and success rates posing major public health challenges. To accelerate access to shorter, safer, and more patient-friendly treatment, Yasa Karsa Insani (YKI), with support from KOICA and the TB Alliance, implemented the Leveraging Innovation for Faster Treatment of Tuberculosis (LIFT-TB) project. The initiative provided multi-year operational and technical assistance to introduce and scale up the WHO-recommended 6–9-month BPaL regimen (bedaquiline, pretomanid, and linezolid) for DR-TB management.


Launched in 2022, LIFT-TB was implemented in collaboration with the Ministry of Health of the Republic of Indonesia, KNCV TB Foundation, and International Tuberculosis Research Centre (ITRC), focusing on operational research and capacity strengthening across 15 hospitals. The project supported protocol development, pretomanid and laboratory equipment procurement, and comprehensive training for health workers and TB survivor groups. Laboratory capacity was enhanced for pretomanid drug susceptibility testing, implemented REDCap-based data systems, and facilitated policy advocacy for national guideline updates.

  • Primary Objective
  • To accelerate the introduction and programmatic scale-up of BPaL/M regimens in Indonesia through operational research, technical assistance, and multi-stakeholder advocacy.

Key Achievements:

  • Achieved a 97.6% treatment success rate, with culture conversion within three months and no relapse cases.
  • Enabled national adoption of BPaL/M regimen, making Indonesia the first country in the Asia-Pacific region to implement it programmatically.
  • Strengthened clinical, laboratory, and pharmacovigilance capacity across 15 hospitals.
  • Enhanced the quality of DR-TB clinical care and management, with a focus on BPaL-based regimen implementation, through clinical mentoring in 24 hospitals across 15 provinces.